EVOQ Therapeutics

3 known investors

EVOQ Therapeutics develops immunotherapies for autoimmune diseases using its proprietary NanoDisc technology, which delivers disease-specific antigens to dendritic cells via subcutaneous administration to restore native immune tolerance. Its approach targets conditions such as Type 1 diabetes, Celiac disease, Multiple Sclerosis, and Lupus.